Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33–35 Weeks Gestational Age in Quebec: A Multicenter Retrospective Study

In 2015, the Quebec Ministry of Health limited palivizumab prophylaxis for respiratory syncytial virus (RSV) in premature infants to those born at <33 weeks gestational age (wGA), unless other indications were present. We compared RSV-related costs for 2 seasons before the change (2013–2014, 2014...

Descripción completa

Detalles Bibliográficos
Autores principales: Papenburg, Jesse, Saleem, Mahwesh, Teselink, Johannes, Li, Abby, Caouette, Georges, Massé, Édith, Lanctôt, Krista L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Original Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360098/
https://www.ncbi.nlm.nih.gov/pubmed/32379195
http://dx.doi.org/10.1097/INF.0000000000002719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360098/
https://www.ncbi.nlm.nih.gov/pubmed/32379195
http://dx.doi.org/10.1097/INF.0000000000002719

Ejemplares similares